Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DRIO vs CLPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DRIO Captures Overall Composite Edge (42.2 HOLD vs 40.4 SELL), While CLPT Leads 3–2 on Growth & Valuation Pillars

DRIO Overall Winner 6-Pillar Tally: DRIO 2 – 3 CLPT (1 Tie) Matrix Metrics: DRIO 5 – 5 CLPT

As of Nov 20, 2026, DarioHealth Corp. (DRIO) captures the overall head-to-head institutional edge over ClearPoint Neuro, Inc. (CLPT) on higher Unified Composite conviction (42.2/100 HOLD vs. 40.4/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while CLPT wins 3–2 across the 6-pillar growth and valuation breakdown. DRIO trades at $1.32 (10.6x Forward P/E, -142.7% operating margin) versus CLPT at $6.91 (12.1x Forward P/E, -66.6% operating margin).

  • Growth vs. Quality Trade-Off: DRIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. CLPT 40.4/100 SELL) and 0.45β · 182% Vol risk profile, whereas CLPT leads top-line expansion (+36.3% YoY revenue growth, 0.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile CLPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DRIO vs CLPT
DRIO NASDAQ Head-to-Head Winner
DarioHealth Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-8.33% 1D
Market Cap $16.3M
TTM Revenue $21M
Forward P/E 10.6x
Beta / 30D Vol 0.45β · 182% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.0%), weak momentum, RSI 24
RSI-14: 24.0 · SMA20: $2.34 · SMA50: $4.46
CLPT NASDAQ
ClearPoint Neuro, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$6.91
-5.47% 1D
Market Cap $234.3M
TTM Revenue $45M
Forward P/E 12.1x
Beta / 30D Vol 1.91β · 86% Vol
Unified Composite Score
40.4 / 100 SELL
Tech 25.0 Fund 48.0 Flow 65.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.4%), weak momentum, RSI 28
RSI-14: 28.3 · SMA20: $9.00 · SMA50: $10.63

6-Pillar Scorecard Institutional Category Breakdown (DRIO 2 – 3 CLPT)

Columns: Metric · DRIO · CLPT
1. Valuation Multiples DRIO
Forward P/E 10.6x 12.1x
Trailing P/E 10.6x 12.1x
PEG Ratio N/M 0.60x
EV / Revenue 0.8x 5.8x
2. Growth & Scale CLPT
Revenue Growth (YoY) +6.1% +36.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $21M $45M
Market Cap $16.3M $234.3M
3. Profitability & Quality CLPT
Gross Margin 61.3% 61.4%
Operating Margin -142.7% -66.6%
Net Profit Margin -159.9% -79.4%
Return on Equity (ROE) -46.6% -167.5%
4. Balance Sheet & Cash Flow CLPT
Cash Generation (TTM) -$28M EBITDA -$33M
Cash Flow Margin -132.8% EBITDA Mgn -73.0%
Net Cash / Leverage $6.37 Book/Sh · -46.6% ROE $28M Net Debt (2.70x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DRIO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 107.7% (7th %ile)
Put/Call OI Skew N/A 2.95x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DRIO (5) vs CLPT (5)
Institutional Metric DRIO CLPT Criterion Row Edge
Market Capitalization
Scale
$16.3M $234.3M Larger Scale CLPT
Trailing P/E Ratio
Valuation
10.6x 12.1x Lower Multiple DRIO
Forward P/E Ratio
Valuation
10.6x 12.1x Lower Multiple DRIO
Revenue Growth (YoY)
Growth
+6.1% +36.3% Higher Growth CLPT
Operating Margin (TTM)
Profitability
-142.7% -66.6% Higher Margin CLPT
Net Profit Margin
Profitability
-159.9% -79.4% Higher Margin CLPT
Return on Equity (ROE)
Capital Efficiency
-46.6% -167.5% Higher ROE DRIO
52-Week Range Position
Momentum
2% ($1–$15) 0% ($7–$20) Stronger Trend DRIO
Beta / 30D Volatility
Risk Regime
0.45β · 182% Vol 1.91β · 86% Vol Lower Realized Risk CLPT
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 40.4 / 100 (SELL) Higher Composite DRIO
Trailing 12M Revenue (USD)
Operating Scale
$21M $45M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.3% 61.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev 0.60x PEG · 5.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M EBITDA ($6.37 Book/Sh · -46.6% ROE) -$33M ($28M Net Debt (2.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLPT +35.99 pp
DRIO: -61.29% · CLPT: -25.3%
3M Horizon CLPT +27.24 pp
DRIO: -81.69% · CLPT: -54.45%
6M Horizon CLPT +43.61 pp
DRIO: -83.21% · CLPT: -39.6%
1Y Horizon CLPT +39.96 pp
DRIO: -90.57% · CLPT: -50.61%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRIO vs CLPT. Trailing 12-month operating profitability (DRIO -142.7% vs CLPT -66.6%) and valuation multiples (DRIO 10.6x vs CLPT 12.1x Forward P/E) are benchmarked directly in Pillar 4 below.

DRIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.3%
Op. Margin-142.7%
ROE / Fwd P/E-46.6% · 10.6x
CLPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$45M
Gross Margin61.4%
Op. Margin-66.6%
ROE / Fwd P/E-167.5% · 12.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DRIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLPT BREAKDOWN
102d in phase · OBV DISTRIBUTION
Current IV 107.7%
IV Percentile 7th %ile
Put/Call OI Skew 2.95x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CLPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DRIO Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $16.3M market capitalization and -142.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLPT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $234.3M market capitalization and -66.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DRIO vs CLPT Key Questions & Quantitative Answers

As of Nov 20, 2026, DarioHealth Corp. (DRIO) captures the overall head-to-head institutional edge over ClearPoint Neuro, Inc. (CLPT) on higher Unified Composite conviction (42.2/100 HOLD vs. 40.4/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while CLPT wins 3–2 across the 6-pillar growth and valuation breakdown. DRIO trades at $1.32 (10.6x Forward P/E, -142.7% operating margin) versus CLPT at $6.91 (12.1x Forward P/E, -66.6% operating margin). Growth vs. Quality Trade-Off: DRIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. CLPT 40.4/100 SELL) and 0.45β · 182% Vol risk profile, whereas CLPT leads top-line expansion (+36.3% YoY revenue growth, 0.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile CLPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLPT leads the Growth & Scale pillar: DRIO posts +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin), compared with CLPT at +36.3% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (61.4% gross margin, -66.6% operating margin). On trailing 12-month operating scale, DRIO generates $21M in USD-normalized revenue versus $45M for CLPT. In operating R&D and SG&A reinvestment, DRIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLPT.

DRIO screens cheaper on headline valuation multiples. DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin), whereas CLPT trades at 12.1x Forward P/E, 12.1x Trailing P/E, 0.60x PEG, and 5.8x EV/Revenue (-73.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRIO (-46.6% ROE) versus CLPT (-167.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk). By comparison, CLPT carries 107.7% implied volatility (7th %ile, Compressed (<25th %ile)), a 2.95x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.91β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.